Short answer
Incyte (INCY) filed its Q1 2026 10-Q quarterly report on Apr 28, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1.3B (up 20.9% year over year) with net income of $303M.
Q1 2026 key financials · XBRL
- Revenue
- $1.3B
- +20.9% YoY
- Net income
- $303M
- +91.7% YoY
- Operating margin
- 23.7%
- EPS (diluted)
- $1.47
- +83.7% YoY
Source: XBRL data from the Incyte (INCY) Q1 2026 10-Q on SEC EDGAR. USD.
Incyte Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No quarterly revenue, YoY comparison, profitability percentages, cash flow, or capital deployment figures provided in excerpt
- Best and worst performing segments or products not quantified in provided text
- Near-term outlook: JAKAFI XR regulatory decision and potential launch anticipated mid-2026
- Development milestones: INCA033989 Phase 3 ET study on track for mid-2026 initiation
- Headwinds: reimbursement, drug pricing, competition, tariffs, trade conflicts, and generic competition risks highlighted
Risk Factors
- New regulatory risk: JAKAFI patent exclusivity expiration in 2028 expected to initiate product-sales decline
- Commercial concentration: JAKAFI expected to remain a significant percentage of total revenues over the next several years
- Reimbursement risk: Payor consolidation may increase rebates, discounts, and other concessions, raising gross-to-net deductions
- Compliance risk: Improper off-label promotion could trigger warning letters, injunctions, fines, or criminal penalties
- Distribution risk: Loss of a major specialty pharmacy or wholesaler could materially harm results of operations and financial condition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Incyte quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.